News brief­ing: Zio­pharm dra­ma con­tin­ues with new let­ter from ac­tivist group; Al­ny­lam, Cen­to­gene join forces on AT­TRv screen­ing pro­gram

As Fri­day’s dead­line to sub­mit writ­ten con­sent ap­proach­es, Wa­ter­Mill As­set Man­age­ment Corp is con­tin­u­ing to put the pres­sure on Zio­pharm On­col­o­gy in its ac­tivist at­tack.

The 3.3% mi­nor­i­ty stake­hold­er sent a new let­ter to in­vestors Tues­day morn­ing, em­pha­siz­ing the need for board­room change ahead of the self-im­posed due date. Wa­ter­Mill again pushed for the full slate of its three board nom­i­nees — Jaime Vieser, Hol­ger Weis and Wa­ter­Mill founder Robert Post­ma — to be se­lect­ed, and de­tailed nu­mer­ous ac­counts of what it says are at­tempts by Zio­pharm to “dis­tort” the truth.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.